PMCB
Income statement / Annual
Last year (2024), PharmaCyte Biotech, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, PharmaCyte Biotech, Inc.'s net income was -$17.24 M.
See PharmaCyte Biotech, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
04/30/2024 |
04/30/2023 |
04/30/2022 |
04/30/2021 |
04/30/2020 |
04/30/2019 |
04/30/2018 |
04/30/2017 |
04/30/2016 |
04/30/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$407,431.00
|
$468,536.00
|
$690,937.00
|
$916,249.00
|
$301,221.00
|
$460,052.00
|
$2.00 M
|
$1.18 M
|
$1.41 M
|
$3.48 M
|
| General & Administrative
Expenses |
$2.12 M
|
$5.99 M
|
$3.70 M
|
$2.71 M
|
$3.53 M
|
$3.64 M
|
$4.98 M
|
$3.26 M
|
$4.67 M
|
$9.99 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$230,500.00
|
| Selling, General &
Administrative Expenses |
$2.12 M
|
$5.99 M
|
$3.70 M
|
$2.71 M
|
$3.53 M
|
$3.64 M
|
$4.98 M
|
$3.26 M
|
$4.67 M
|
$10.22 M
|
| Other Expenses |
$6.00 M |
$202,002.00 |
-$4,283.00 |
-$1,188.00 |
-$40.00 |
$33,401.00 |
$152,588.00 |
$2.52 M |
$10,540.00 |
$3.34 M |
| Operating Expenses |
$8.52 M |
$6.46 M |
$4.39 M |
$3.62 M |
$3.83 M |
$4.10 M |
$6.98 M |
$4.44 M |
$6.07 M |
$13.70 M |
| Cost And Expenses |
$8.52 M |
$6.46 M |
$4.39 M |
$3.62 M |
$3.83 M |
$4.10 M |
$6.98 M |
$4.44 M |
$6.07 M |
$13.70 M |
| Interest Income |
$3.40 M |
$1.94 M |
$157,645.00 |
$3.05 |
$0.45 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$509.00 |
$3,046.00 |
$453.00 |
$0.00 |
$0.00 |
-$1,539.00 |
-$1,191.00 |
-$4,938.00 |
| Depreciation &
Amortization |
$0.00
|
$6.46 M
|
$4.39 M
|
$3.62 M
|
$3.83 M
|
$4.10 M
|
$6.98 M
|
$4.44 M
|
$6.07 M
|
$492,049.00
|
| EBITDA |
-$8.52 M
|
-$4.32 M
|
-$4.24 M
|
-$3.62 M
|
-$3.83 M
|
-$4.10 M
|
-$6.98 M
|
-$4.44 M
|
-$6.07 M
|
-$13.20 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$8.72 M
|
$202,002.00
|
$152,853.00
|
$71,745.00
|
-$493.00
|
$33,401.00
|
$152,588.00
|
-$1,539.00
|
$10,540.00
|
$2.85 M
|
| Income Before Tax |
-$17.24 M |
-$4.32 M |
-$4.24 M |
-$3.55 M |
-$3.83 M |
-$4.07 M |
-$6.83 M |
-$4.44 M |
-$6.06 M |
-$10.85 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$1.94 M |
-$153,362.00 |
$3,046.00 |
$453.00 |
-$33,401.00 |
-$152,588.00 |
-$4,442.15 |
-$4,882.13 |
$4,938.00 |
| Net Income |
-$17.24 M |
-$4.32 M |
-$4.09 M |
-$3.55 M |
-$3.83 M |
-$4.07 M |
-$6.83 M |
-$4.44 M |
-$6.06 M |
-$10.85 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.8 |
-0.22 |
-0.26 |
-2.46 |
-4.23 |
-5.55 |
-10.57 |
-7.89 |
-12.09 |
-23.11 |
| EPS Diluted |
-1.8 |
-0.22 |
-0.26 |
-2.46 |
-4.23 |
-5.55 |
-10.57 |
-7.88 |
-12.08 |
-23.11 |
| Weighted Average Shares
Out |
$9.58 M
|
$19.49 M
|
$15.52 M
|
$1.45 M
|
$903,811.00
|
$733,402.00
|
$645,761.00
|
$563,538.00
|
$501,602.00
|
$469,786.00
|
| Weighted Average Shares
Out Diluted |
$9.58 M
|
$19.49 M
|
$15.52 M
|
$1.45 M
|
$903,811.00
|
$733,402.00
|
$646,084.00
|
$563,820.00
|
$501,852.00
|
$469,786.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
